Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial resultsSabino De Placido, Grazia Arpino, Fabio Puglisi et al.|The Breast|2018Cited by 35
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational studyFrancesco Schettini, Lucia Del Mastro, Benedetta Conte et al.|ESMO Open|2021Cited by 22
Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design SimulationLorenzo Gerratana, Massimo Cristofanilli, Jean‐Yves Pierga et al.|The Oncologist|2022Cited by 13
Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysisCarmine De Angelis, Grazia Arpino, Massimo Di Maïo et al.|Oncotarget|2017Cited by 3